PureTech Health plc: PureTech Forms Clinical Advisory Board for Idiopathic Pulmonary Fibrosis and Related Lung Disorders
idiopathic pulmonary fibrosis and other progressive fibrosing interstitial lung diseases PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ( PureTech or the Company ), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced the formation of its Clinical Advisory Board for idiopathic pulmonary fibrosis (IPF) and other progressive fibrosing interstitial lung diseases (PF-ILDs). Comprised of physicians and researchers with deep expertise in the clinical development of novel therapies in PF-ILDs, the advisory group will work closely with PureTech as it advances LYT-100 (deupirfenidone).
United-states
Netherlands
Michigan
France
Bill-bradford
Claude-bernard-lyon
Marlies-wijsenbeek
Toby-maher
Vincent-cottin
Allison-mead-talbot
Daphne-zohar
Stephanie-simon